A genetic variation in people with East Asian descent could be the reason why some patients fail to respond to popular cancer drugs.
Researchers led by S Tiong Ong of the Cancer and Stem Cell Biology at Duke University Medical Center found that patients with genetic variation in the EGFR gene fail to respond to popular cancer drugs known as tyrosine kinase inhibitor (TKI) drugs which are used to treat certain blood cell cancers such as chronic myelogenous leukemia (CML).
Women and Cancer
Cancer is one of the frequently talked about and most feared disease that falls under the genre of lifestyle diseases that have evolved, rather rapidly, in the past two decades.
Advertisement
The researchers said that their findings will come as good news for those with the genetic variation as they can get a more specialized treatment by including class of drugs called BH3-mimetics to their existing TKI treatment.
"When the BH3 drugs were added to the TKI therapy in experiments conducted on cancer cells with the BIM gene variant, we were able to overcome the resistance conferred by the gene. Our next step will be to bring this to clinical trials with patients", Tiong Ong said.
Source: Medindia
Source: Medindia
Pre-Cancerous Lesions
Encyclopedia section of medindia gives general information about Pre Cancerous Lesions
Advertisement
Advertisement
|
Advertisement
Recommended Reading
Latest Cancer News
The mechanism by which the kinases cause inflammation has been discovered by scientists.
Pancreatic cancer cases are on the rise. The biomarker approach could reduce the chance of developing pancreatic cancer.
New combination of medications trametinib and entinostat were found to decrease lung cancer in mice.
Combination treatment with TALZENNA and XTANDI was found to benefit prostate cancer patients, revealed study.
In leukemia patients, reduced amounts of dietary vitamin A is associated with a higher risk and severity of pancreatitis.